Category Added in a WPeMatico Campaign
YolTech Therapeutics Receives FDA Clearance to Initiate Phase 2/3 Study of In Vivo Gene-Editing Therapy YOLT-202 in Alpha-1 Antitrypsin Deficiency (AATD)
SHANGHAI--(BUSINESS WIRE)--YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene-editing therapies, today announced [...]